NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. The Company offers services, such as Mitochondrial Replacement Therapy In Reproductive, Intrauterine Insemination (IUI), Mitochondrial replacement therapy (MRT) techniques, In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI), semen analysis, testicular / epididymal sperm aspiration or extraction / percutaneous epididymal sperm aspiration, embryo transfer, chromosome screening and egg freezing. The Company’s clinics are located in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. MRT involves an additional egg from a third person, and manipulating both the recipient egg and the donor egg.
企業コードNIVFW
会社名NewGenIvf Group Ltd
上場日Feb 15, 2022
最高経営責任者「CEO」Mr. Claudius Tsang
従業員数- -
証券種類Company Warrant
決算期末- -
本社所在地Level 39, Marina Bay Financial Centre
都市
証券取引所NASDAQ Capital Market Consolidated
国Singapore
郵便番号018983
電話番号6568185796
ウェブサイトhttps://newgenivf.com/
企業コードNIVFW
上場日Feb 15, 2022
最高経営責任者「CEO」Mr. Claudius Tsang
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし